Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic DermatitisBenzinga • 02/10/22
FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic DermatitisPRNewsWire • 02/10/22
Regeneron Pharmaceuticals, Inc. (REGN) CEO Dr. Len Schleifer on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/04/22
Regeneron's Q4 Sales, Profits More Than Double With Boost From COVID-19 Treatment SalesBenzinga • 02/04/22
Regeneron shares up premarket after Q4 revenue doubles and blows past estimatesMarket Watch • 02/04/22
Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating ResultsPRNewsWire • 02/04/22
Positive Dupixent® (dupilumab) Data Across Five Diseases with Underlying Type 2 Inflammation to be Presented at 2022 AAAAI Annual MeetingPRNewsWire • 02/01/22
CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 InflammationBenzinga • 01/31/22
CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 InflammationPRNewsWire • 01/31/22
Regeneron, Sanofi withdraw application for Libtaya as a cervical cancer treatment in the U.S.Market Watch • 01/28/22
Regeneron and Sanofi Provide Regulatory Update on Libtayo® (cemiplimab-rwlc) in Advanced Cervical CancerPRNewsWire • 01/28/22